Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(42.9%)
Early Phase 1
1(14.3%)
Phase 1
1(14.3%)
N/A
1(14.3%)
Phase 3
1(14.3%)
7Total
Phase 2(3)
Early Phase 1(1)
Phase 1(1)
N/A(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06720285Early Phase 1Completed

The Efficacy of Regional Scalp Block in Craniotomy

Role: collaborator

NCT06688318Phase 1Active Not Recruiting

Effectivity of Allogenic Umbilical Cord Mesenchymal Stem Cells Conditioned Media for Osteoarthritis of the Knee Joint

Role: lead

NCT06642480Not ApplicableCompleted

Distribution of CYP2D6 Multiplication, CYP2D6*5, and Clinical Implications in Postoperative Patients Receiving Tramadol Analgesia in the Minangkabau Ethnic Group, Indonesia

Role: lead

NCT04979065Phase 2Completed

Nutrition, Immunity, and Covid-19 in Obese People

Role: collaborator

NCT05119218Completed

Gut Microbiota Stunted Children NTT

Role: collaborator

NCT05296863Phase 3Completed

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

Role: collaborator

NCT05216562Phase 2Unknown

Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients

Role: collaborator

NCT05132972Phase 2Unknown

Allogenic UCMSCs as Adjuvant Therapy for Severe COVID-19 Patients

Role: lead

All 8 trials loaded